Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twice-weekly prednisolone in infants and young boys with Duchenne muscular dystrophy
NCT02167217Phase 2Completed
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2014
- Primary completion
- Feb 2017
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of prednisolone in Duchenne muscular dystrophy (DMD), sponsored by Washington University School of Medicine. Primary endpoint: Bayley-III Gross Motor Scaled Score at 12 months. Started Apr 2014; status: completed.
02
Drugs
prednisolone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02167217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02167217.